scholarly journals Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

Hepatology ◽  
2010 ◽  
Vol 51 (6) ◽  
pp. 1897-1903 ◽  
Author(s):  
Moises Diago ◽  
Mitchell L. Shiffman ◽  
Jean-Pierre Bronowicki ◽  
Stefan Zeuzem ◽  
Maribel Rodriguez-Torres ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Genotype ◽  
Genotype 2 ◽  
Peginterferon Alfa

Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: a randomised trial

Gut ◽  
2014 ◽  
Vol 64 (2) ◽  
pp. 303-311 ◽  
Author(s):  
Chen-Hua Liu ◽  
Chun-Jen Liu ◽  
Chung-Feng Huang ◽  
Jou-Wei Lin ◽  
Chia-Yen Dai ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Low Dose ◽  
Randomised Trial ◽  
Virus Genotype ◽  
Genotype 2 ◽  
Treatment Naïve ◽  
Peginterferon Alfa

scholarly journals Peginterferon Alfa-2a plus Ribavirin in Japanese Patients Infected with Hepatitis C Virus Genotype 2 Who Failed Previous Interferon Therapy

2013 ◽  
Vol 10 (1) ◽  
pp. 43-49 ◽  
Author(s):  
Tatsuo Kanda ◽  
Shingo Nakamoto ◽  
Takayoshi Nishino ◽  
Nobuo Takada ◽  
Akihito Tsubota ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Interferon Therapy ◽  
Japanese Patients ◽  
Virus Genotype ◽  
Genotype 2 ◽  
Peginterferon Alfa

scholarly journals The effectiveness and safety of sofosbuvir‐ledipasvir for patients with hepatitis C virus genotype 2 infection

2021 ◽  
Author(s):  
Po‐Yueh Chen ◽  
Hsin‐Yi Yang ◽  
Chu‐Kuang Chou ◽  
Li‐Jen Chang ◽  
Ming‐Tse Hsu ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Virus Genotype ◽  
Genotype 2

scholarly journals Interplay of Amino Acid Residues at Positions 28 and 31 in NS5A Defines Resistance Pathways in Hepatitis C Virus Genotype 2

2019 ◽  
Vol 63 (12) ◽  
Author(s):  
Ernest Asante-Appiah ◽  
Paul Ingravallo ◽  
Patricia McMonagle ◽  
Karin Bystol ◽  
Ellen Xia ◽  
...  
Keyword(s):  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Amino Acid ◽  
Treatment Outcomes ◽  
Cross Talk ◽  
Site Directed Mutagenesis ◽  
Virus Genotype ◽  
Ns5a Inhibitor ◽  
Genotype 2 ◽  
Antiviral Activities

ABSTRACT Hepatitis C virus (HCV) genotype 2 (GT2) represents approximately 9% of all viral infections globally. While treatment outcomes for GT2-infected patients have improved substantially with direct-acting antiviral agents (DAAs) compared to alpha interferon, the presence of polymorphisms in NS5A can impact the efficacy of NS5A inhibitor-containing regimens. Thus, pathways of NS5A resistance were explored in GT2 subtypes using elbasvir, an NS5A inhibitor with broad genotype activity. Resistance selection studies, resistance analysis in NS5A-inhibitor treated virologic failures, and analyses of antiviral activities in replicons bearing a panel of GT2 subtype sequences and amino acid substitutions introduced by site-directed mutagenesis were performed to define determinants of inhibitor susceptibility. Elbasvir showed differential antiviral activities in replicons bearing GT2 sequences. The 50% effective concentration (EC50) values for replicons bearing reference NS5A sequences for GT2a and GT2b were 0.003 and 3.4 nM, respectively. Studies performed with recombinant replicons demonstrated cross talk between amino acid positions 28 and 31. The combination of phenylalanine and methionine at positions 28 and 31, respectively, conferred the highest potency reduction for elbasvir in GT2a and GT2b. This combination was observed in failures seen in the C-SCAPE trial. Addition of grazoprevir, an NS3/4A protease inhibitor, to elbasvir more effectively suppressed the emergence of resistance in GT2 at modest inhibitor concentrations (3× EC90). Ruzasvir, a potent, pan-genotype NS5A inhibitor, successfully inhibited replicons bearing GT2 resistance-associated substitutions (RASs) at positions 28 and 31. The results demonstrate that cross talk between amino acids at positions 28 and 31 in NS5A modulated inhibitor potency and may impact treatment outcomes in some HCV GT2-infected patients.

Sign in / Sign up

Export Citation Format

Share Document